Glucotrack (Nasdaq:GCTK) announced today that it appointed Erin Carter to its board of directors, naming her chair of its audit committee.
Carter’s appointment comes just days after the implantable continuous glucose monitor (CGM) maker named Drinda Benjamin VP of marketing. She becomes a member of the board and chair of the audit committee, effective immediately.
“We are delighted to have Erin join our board of directors,” said Paul Goode, CEO of Glucotrack. “She brings a wealth of financial knowledge and expertise in working with young companies and guiding them through strategic growth and expansion. She will be a tremendous asset as we look ahead to growing the organization and moving into the commercialization phase.”
Rutherford, New Jersey-based Glucotrack designed its CGM for patients with type 1 and type 2 insulin-dependent diabetes.
Carter brings to Glucotrack 30 years of executive-level finance experience in the medical device industry. From 2012 until March of this year, she served in a number of senior roles at medtech giant Medtronic. Most recently, she held the post of chief financial officer and VP of finance for the Medtronic Neuroscience division.
Additionally, while at Medtronic, Carter helped to grow its Gastrointestinal Solutions division. Before Medtronic, she served as director of finance at Boston Scientific and VP of accounting and reporting at UnitedHealth Group. Prior to that, she was assistant controller for Arterial Vascular Engineering, managing two acquisitions before the company’s subsequent sale to Medtronic.
“I am excited to join the Glucotrack board at such a pivotal time in the company’s evolution,” Carter said. “I look forward to working with the Company’s leadership team to advance its mission of developing and commercializing innovative technologies to improve the lives of people with diabetes and to build long-term value for shareholders.”